Response to “Methodological and Mechanistic Considerations on Duration-Dependent Pulsed Radiofrequency for Rheumatoid Arthritis” [Response to Letter] Authors: Xin Li, Meng Wang, YingDi Wang, Gang Zhao, Ju Gao, Cunjin Wang Published: 2026 Dear editor We thank the authors of the Letter for their thoughtful comments and constructive suggestions.1 Their concerns mainly relate to the translational boundary, behavioral specificity, mechanistic causality, long-term durability, and neural safety of duration-dependent pulsed radio frequency (PRF) in CIA rats. We agree that these issues deserve further investigation and will be important for refining PRF protocols for inflammatory arthritis. Regarding the treatment plans for PRF, the present study aimed to compare the effects of three single-session durations—1, 2, and 3 minutes—on joint pain, inflammation, and pathological damage in CIA rats, under conditions of fixed treatment frequency and fixed intervals, rather than evaluating all possible treatment regimens. In all PRF groups, stimulation was delivered to the L4–L6 dorsal root ganglion (DRG) at 42°C and 20 Hz, administered once every 20 minutes for a total of four sessions, with only the single-session stimulation duration being varied. This experimental design was adopted to minimize confounding factors and directly observe the “duration-dependent” effects. If treatment frequency, intervals, and the number of sessions were altered simultaneously, it would be difficult to determine whether changes in therapeutic efficacy were attributable to single-session duration, cumulative stimulation dose, or inter-session intervals. Therefore, our conclusions should be interpreted as follows: under the current experimental conditions, the therapeutic effects of 2-minute PRF were superior to those of 1-minute PRF and comparable to those of 3-minute PRF, suggesting that in this CIA model, a duration of 2 minutes may have reached a plateau in therapeutic efficacy. In future studies, a 2×3 or 3×3 factorial design will be employed to further investigate the interactions between “duration × treatment frequency/interval”, such as four sessions per day, once weekly for three consecutive weeks, or once every other day for two consecutive weeks, in order to verify whether this optimal duration remains effective under different intervals or repeated-session protocols. In terms of pain assessment, we acknowledge that the tail-flick test primarily reflects thermal nociceptive reflexes rather than serving as a direct indicator of arthritis-specific joint pain. The limitations of this method have been explicitly addressed in the Discussion section of this study, and it has been proposed that future research will incorporate multiple behavioral evaluation methods—such as the von Frey filament test and weight-bearing asymmetry assessment—to refine the evaluation system for joint-specific pain. It should be further clarified that animal models of arthritis exhibit a pronounced thermal hyperalgesic phenotype.2,3 As a well-established quantitative technique for detecting thermal nociception, the tail-flick latency effectively reflects the degree of overall nociceptive sensitization in animals and was therefore included in the pain assessment framework of this study. Moreover, the interpretation of the antinociceptive effects of PRF in this study does not rely solely on tail-flick latency results. The study has demonstrated that PRF intervention effectively alleviates ankle joint swelling, improves histological joint damage, downregulates Mankin/OARSI joint scores, suppresses Ki67 expression in synovial tissue, and significantly reduces levels of inflammatory cytokines in the joints. These multiple empirical findings—encompassing joint structural restoration and inflammation inhibition—collectively support the ameliorative effects of PRF on the pathological phenotypes of arthritis. In future studies, we will incorporate the von Frey test, weight-bearing asymmetry, and gait analysis to more accurately characterize joint-specific pain and function. Regarding the causal relationship between TRPA1 and TRPV1, we acknowledge that the current data suggest a correlation rather than a definitive causal mediation. Our conclusion—that “PRF may function as a powerful analgesic and anti-inflammatory agent by modulating the expression dynamics of TRPA1 and TRPV1 channels in the synovium”—is intended as a correlation-based inference, not a claim of proven causality. We believe this distinction has been appropriately conveyed through our cautious wording. Multiple lines of evidence support the functional role of TRPA1/TRPV1 in our findings. First, both channels are well-established nociceptors that play important roles in inflammatory pain, neurogenic inflammation, and synovial inflammatory responses.4–8 Second, our previous study demonstrated that PRF acting on the DRG resulted in a more pronounced downregulation of TRPA1 and TRPV1 compared to intra-articular PRF, suggesting that DRG-PRF exerts neuromodulatory effects on these channels beyond subsequent anti-inflammatory effects.9 Third, recent studies have shown that PRF can inhibit axonal transport in small DRG neurons and suppress the secretion of CGRP (Calcitonin Gene-Related Peptide) and substance P—neuropeptides closely associated with TRP channel signaling and persistent inflammation.10 Future studies employing TRPA1/TRPV1 agonists, antagonists, knock-out models, and rescue experiments are warranted to determine whether these channels are necessary mediators of PRF-induced analgesic and anti-inflammatory effects. Regarding the observation window, we agree that 14 days is insufficient to prove long-term disease-modifying or chondroprotective efficacy in a chronic progressive disease such as RA. Our study evaluated short-term analgesic, anti-inflammatory and histopathological changes after PRF applied at week 9 after CIA induction. Therefore, the findings should be interpreted as evidence of short-term improvement rather than definitive prevention of late irreversible joint destruction. Longer follow-up studies with micro-CT, longitudinal histology and functional pain testing are planned. In terms of safety, we recognize that prolonged PRF exposure necessitates a systematic neuro-safety assessment. Although 42°C PRF is generally regarded as a neuromodulatory rather than neurodestructive technique and offers a higher safety profile compared to conventional continuous radiofrequency,11 experimental evidence indicates that radiofrequency exposure may still induce varying degrees of biological and morphological changes depending on parameter differences.12 Therefore, this study favors a 2-min duration, not solely because of its significant therapeutic efficacy, but because no significant difference in efficacy was observed between 2 min and 3 min, suggesting that the 2-min duration may have reached a therapeutic plateau. In the absence of clear safety benefits from longer intervention durations and given the lack of comprehensive long-term neuro-safety data, selecting a shorter effective intervention duration aligns more closely with the risk–benefit balance in both clinical and basic research. Subsequent studies will integrate multiple technical approaches, including Nissl staining of the DRG, nerve ultrastructural analysis, detection of neuronal apoptosis markers and glial cell activation markers, as well as sensorimotor behavioral assessments, to systematically elucidate the neuro-safety profile of prolonged PRF intervention protocols and to refine the parameter safety framework for PRF interventions. We once again sincerely thank the authors of the Letter for their thorough review and insightful comments on this study. The five concerns they raised—single treatment plans, pain assessment metrics, the causal relationship of the TRP pathway, the observation period, and safety evaluation—are highly consistent with both our current and future research directions. We believe that through systematic experimental investigations in the future, these methodological and mechanistic issues will be gradually addressed, thereby providing more robust evidence to support the preliminary findings of this study on optimizing PRF duration for the treatment of RA and further enhancing its translational value. Disclosure The authors report no conflicts of interest in this communication. References